TINA JOSEPH: Open Payments
NPI 1275163636 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 16 payments from 10 companies in 2025. Trend: 2023 $133 · 2024 $520 · 2025 $471
Food & beverage: $277Education: $194
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $194 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $95 |
| Madrigal Pharmaceuticals | 2 | $36 |
| Merck Sharp & Dohme LLC | 1 | $34 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| GENZYME CORPORATION | 1 | $20 |
| ABBVIE INC. | 1 | $20 |
| Novo Nordisk Inc | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Caris MPI, Inc. | 1 | $15 |
Products named: Trodelvy, XIFAXAN, REZDIFFRA, KEYTRUDA, Smoflipid, CERDELGA, TEFLARO, Wegovy.
Industry payments across TX — which companies pay providers there.
